β-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial

Area of Science:

• Cardiology
• Hepatology
• Pharmacology

Background:

• Cirrhotic cardiomyopathy involves impaired heart contractility due to chronic high catecholamine exposure affecting beta-adrenergic receptors.
• Understanding the pathogenesis is crucial for developing effective treatments.

Purpose of the Study:

• To investigate if beta-blockade with metoprolol can reverse cardiac dysfunction and morphological changes in cirrhotic cardiomyopathy.
• To evaluate the efficacy of metoprolol in improving cardiac output response to stress.

Main Methods:

• A prospective randomized trial involving 78 patients (18-60 years) with abnormal dobutamine stress echocardiography response, excluding primary cardiac disease or alcohol history.
• Patients received either metoprolol or placebo for 6 months, with the primary endpoint being a >30% increase in left ventricle stroke volume.
• Cardiac function, morphology, and relevant biomarkers (noradrenaline, renin, troponin) were assessed.

Main Results:

• A trend towards improved stroke volume was observed in the metoprolol group (7.3%) versus placebo (24.3%), though not statistically significant (P=0.057).
• No significant differences in diastolic dysfunction, echocardiographic morphology parameters, or biomarker levels were found between groups after treatment.
• There were no significant differences in cirrhosis-related clinical events, including hospitalizations and mortality.

Conclusions:

• Six months of metoprolol therapy did not significantly improve cardiac function or morphology in patients with cirrhotic cardiomyopathy.
• Beta-blockade with metoprolol is not an effective treatment for reversing cardiac changes in this patient population.